Premium
Exogenous Cushing syndrome from an unexpected source of systemic steroids
Author(s) -
O'Brien Kathleen F.,
DeKlotz Cynthia Marie Carver,
Silverman Robert A.
Publication year - 2018
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13456
Subject(s) - cushingoid , medicine , prednisone , atopic dermatitis , prednisolone , dermatology , hirsutism , adverse effect , food and drug administration , pediatrics , pharmacology , insulin resistance , polycystic ovary , insulin
A 12‐year‐old Hispanic boy with chronic atopic dermatitis and cushingoid features presented to our institution. He was being treated with an unknown quantity of oral prednisolone 15 mg/5 mL, equivalent to 70 mg/m 2 /d of oral prednisone, purchased over the counter in El Salvador. Systemic corticosteroids are not recommended for chronic therapy of atopic dermatitis because of their significant adverse effects. Foreign‐sourced pharmaceuticals account for almost half of the drugs consumed in the United States, which means that, to protect our patients, medical providers must inquire about and report unsafe medications deemed legal outside the United States to the Food and Drug Administration.